Journal article

Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation


Authors listAli, S; Nguyen, DQ; Falk, W; Martin, MU

Publication year2010

Pages1512-1516

JournalBiochemical and Biophysical Research Communications

Volume number391

Issue number3

ISSN0006-291X

DOI Linkhttps://doi.org/10.1016/j.bbrc.2009.12.107

PublisherElsevier


Abstract
IL-33 is a member of the IL-1 family of cytokines with dual function which either activates cells via the IL-33 receptor in a paracrine fashion or translocates to the nucleus to regulate gene transcription in an intracrine manner. We show that full length murine IL-33 is active as a cytokine and that it is not processed by caspase I to mature IL-33 but instead cleaved by caspase 3 at aa175 to yield two products which are both unable to bind to the IL-33 receptor. Full length IL-33 and its N-terminal caspase 3 breakdown product, however, translocate to the nucleus. Finally, bioactive IL-33 is not released by cells constitutively or after activation. This suggests that IL-33 is not a classical cytokine but exerts its function in the nucleus of intact cells and only activates others cells via its receptor as an alarm mediator after destruction of the producing cell. (c) 2009 Elsevier Inc. All rights reserved.



Citation Styles

Harvard Citation styleAli, S., Nguyen, D., Falk, W. and Martin, M. (2010) Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation, Biochemical and Biophysical Research Communications, 391(3), pp. 1512-1516. https://doi.org/10.1016/j.bbrc.2009.12.107

APA Citation styleAli, S., Nguyen, D., Falk, W., & Martin, M. (2010). Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochemical and Biophysical Research Communications. 391(3), 1512-1516. https://doi.org/10.1016/j.bbrc.2009.12.107


Last updated on 2025-21-05 at 14:08